Amphetamine Abuse
Find comprehensive information on Amphetamine Abuse, including diagnostic criteria, clinical documentation guidelines, and medical coding for Amphetamine Use Disorder and Stimulant Abuse. Learn about signs, symptoms, treatment options, and best practices for healthcare professionals dealing with amphetamine addiction and substance use disorders. This resource provides valuable insights for accurate and efficient medical coding and documentation related to amphetamine-related diagnoses.
Misuse of amphetamines leading to significant impairment or distress.
Increased heart rate, elevated blood pressure, agitation, paranoia, weight loss, insomnia.
Outpatient clinics, addiction treatment centers, emergency rooms, hospitals.
ICD-10 Code Families
Complete code families applicable to F15.10
When to use each related code
| Description | When to use |
|---|---|
| Amphetamine abuse leading to significant impairment or distress. | Primary diagnosis for harmful amphetamine use. Consider stimulant-induced disorders. |
| Stimulant use causing intoxication, withdrawal, or other mental/physical problems. | For amphetamine or other stimulant-related disorders like intoxication or withdrawal. If specific substance known, code for that. |
| Substance use disorder not otherwise specified. | Use only when a more specific substance use disorder diagnosis cannot be made. Avoid if possible. |
Best-practice checklist
- ✓Amphetamine abuse DSM-5 criteria documented
- ✓Severity (mild, moderate, severe) specified
- ✓Evidence of impairment/distress noted
- ✓Onset and duration of amphetamine use
- ✓Specific amphetamine used (if known)
Common pitfalls to avoid
Coding requires specifying the type of amphetamine (e.g., dextroamphetamine, methamphetamine) for accurate billing and data analysis.
Distinguishing between abuse and dependence is crucial for proper coding (e.g., F15.10 vs. F15.20) and impacts severity reflection.
Documenting and coding co-occurring mental health disorders (e.g., anxiety, depression) is essential for complete patient representation and appropriate care.
Best-practice tips
- 01ICD-10 F15.10, document amphetamine type, frequency, and route.
- 02CPT 99202-99215 for E/M, justify medical necessity in documentation.
- 03Screen for co-occurring disorders, document using DSM-5 criteria.
- 04Behavioral therapy (CBT) is effective, document treatment plan and progress.
- 05Monitor for cardiovascular complications, document vital signs and interventions.
Step-by-step checklist
- 1
Verify amphetamine use (urine drug screen).
- 2
Document frequency, amount, and route of administration.
- 3
Assess for amphetamine withdrawal symptoms (ICD-10 F15.2).
- 4
Screen for co-occurring mental health disorders (e.g., anxiety, depression).
Ready-to-paste narrative
Patient presents with symptoms consistent with amphetamine abuse, also known as stimulant abuse or amphetamine use disorder. The patient reports a pattern of amphetamine use leading to clinically significant impairment or distress, as manifested by continued use despite negative consequences. Symptoms include increased heart rate, elevated blood pressure, dilated pupils, insomnia, restlessness, and agitation. The patient acknowledges cravings for amphetamines and difficulty controlling amphetamine use. The patient's social and occupational functioning has been negatively impacted by their amphetamine use, as evidenced by job loss and strained family relationships. Differential diagnoses considered include other substance use disorders, anxiety disorders, and mood disorders. Assessment includes a thorough substance use history, mental status examination, and laboratory testing to assess for amphetamine toxicity and rule out other medical conditions. Treatment plan includes referral to addiction medicine specialist for further evaluation and management, consideration for cognitive behavioral therapy (CBT) and motivational interviewing, and exploration of pharmacotherapy options for amphetamine dependence. ICD-10 code F15.10 will be applied for amphetamine abuse, unspecified. Patient education provided regarding the risks and consequences of amphetamine use and the importance of adherence to the treatment plan. Follow-up appointment scheduled to monitor progress and adjust treatment as needed.
Common questions and answers
What are the most effective evidence-based interventions for amphetamine use disorder in adolescents, considering both pharmacological and non-pharmacological approaches?+
While no FDA-approved medications currently exist for treating amphetamine use disorder (AUD) specifically in adolescents, several evidence-based non-pharmacological interventions demonstrate efficacy. Contingency management (CM), utilizing positive reinforcement for abstinence, is a well-established approach. Cognitive behavioral therapy (CBT) helps adolescents identify triggers, develop coping mechanisms, and modify drug-related cognitions. Family-based interventions, such as multidimensional family therapy (MDFT) or brief strategic family therapy (BSFT), address family dynamics and communication patterns contributing to substance use. Motivational interviewing (MI) can increase readiness to change and engagement in treatment. For co-occurring mental health conditions, integrated treatment models addressing both AUD and other disorders are crucial. Explore how combining CBT with family therapy can improve outcomes in adolescent amphetamine abuse treatment. Consider implementing CM alongside therapy to enhance abstinence rates. Further research is needed to determine the effectiveness of medications like naltrexone or bupropion, currently utilized in adult AUD, for adolescent populations.
How can clinicians differentiate amphetamine intoxication from other stimulant-induced presentations (e.g., cocaine, synthetic cathinones) and psychiatric disorders (e.g., bipolar mania, schizophrenia) during the initial assessment?+
Differentiating amphetamine intoxication from other stimulant-induced states and primary psychiatric disorders requires careful consideration of clinical presentation, history, and toxicological testing. While all stimulants can cause agitation, elevated mood, and tachycardia, some distinguishing features may exist. Amphetamine intoxication may present with more prominent stereotyped behaviors (e.g., repetitive movements, picking) and paranoia compared to cocaine. Synthetic cathinones can produce more pronounced sympathomimetic effects and prolonged duration of action. Distinguishing from bipolar mania requires assessing the longitudinal course; mania typically involves episodic mood elevation interspersed with periods of euthymia or depression, unlike the acute onset seen in intoxication. Similarly, psychotic symptoms in amphetamine intoxication are usually transient and resolve upon drug clearance, whereas schizophrenia involves persistent and pervasive psychotic features. Comprehensive history, including substance use patterns and psychiatric history, helps in differentiating these conditions. Urine drug screening confirms the presence of amphetamines, but cannot always distinguish between specific stimulants. Consider implementing standardized screening tools for substance use and co-occurring disorders. Learn more about specific symptoms and timelines associated with various stimulant intoxications to improve diagnostic accuracy.
What are the best practices for managing amphetamine withdrawal symptoms in a primary care setting, including strategies for addressing cravings, sleep disturbances, and potential psychiatric complications?+
Managing amphetamine withdrawal in a primary care setting necessitates a comprehensive approach addressing both physical and psychological symptoms. Initially, focus on patient safety and stabilization. Severe withdrawal symptoms, including suicidal ideation or psychosis, may require referral to a higher level of care. For less severe cases, a combination of supportive care and symptomatic management is appropriate. Address cravings through counseling, exploring potential triggers and developing coping strategies. Non-pharmacological approaches like mindfulness and relaxation techniques can be helpful. Sleep disturbances often accompany withdrawal; encourage good sleep hygiene practices and consider short-term use of sleep aids if necessary. Monitor for potential psychiatric complications like depression, anxiety, and increased irritability. Referral to mental health services is crucial for patients experiencing significant psychiatric sequelae. Consider implementing regular monitoring of vital signs and mental status during withdrawal. Learn more about integrated treatment approaches combining primary care with mental health and addiction services to optimize patient outcomes. Explore how motivational interviewing can enhance patient engagement in long-term recovery.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.